Our product development programs target specific subsets of cancer, and we seek to simultaneously develop, with partners, companion diagnostics that direct our product candidates to the patients most likely to benefit from their use Our development programs are targeted at specific subsets of cancer, combining personalized medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them We are a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets We believe this approach to personalized medicine - to deliver the right drug to the right patient at the right time - represents the future of cancer therapy For our third product candidate, we are in the discovery phase for a compound to treat patients with gastrointestinal stromal tumors, or GIST, whose cancer is resistant to current therapies